NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia

• Jana Hof,
• Corinne Kox,
• Stefanie Groeneveld-Krentz,
• Obul R. Bandapalli,
• Leonid Karawajew,
• Katharina Schedel,
• Joachim B. Kunz,
• Cornelia Eckert,
• Wolf-Dieter Ludwig,
• Richard Ratei,
• Peter Rhein,
• Günter Henze,
• Martina U. Muckenthaler,
• Andreas E. Kulozik,
• Arend von Stackelberg,
• Renate Kirschner-Schwabe

Affiliations

Jana Hof

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin;German Cancer Consortium (DKTK), and German Cancer Research Center (DKFZ), Heidelberg, Germany

Corinne Kox

Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany;European Molecular Biology Laboratory (EMBL), Heidelberg, Germany

Stefanie Groeneveld-Krentz

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin

Obul R. Bandapalli

Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany

Leonid Karawajew

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin

Katharina Schedel

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin

Joachim B. Kunz

Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany

Cornelia Eckert

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin;German Cancer Consortium (DKTK), and German Cancer Research Center (DKFZ), Heidelberg, Germany

Wolf-Dieter Ludwig

HELIOS Medical Clinic Berlin-Buch, Clinic for Hematology, Oncology, Tumor Immunology and Palliative Care, Berlin

Richard Ratei

HELIOS Medical Clinic Berlin-Buch, Clinic for Hematology, Oncology, Tumor Immunology and Palliative Care, Berlin

Peter Rhein

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin

Günter Henze

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin

Martina U. Muckenthaler

Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany

Andreas E. Kulozik

Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany

Arend von Stackelberg

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin

Renate Kirschner-Schwabe

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin;German Cancer Consortium (DKTK), and German Cancer Research Center (DKFZ), Heidelberg, Germany